Display options
Cite
Timour Q, Bui-Xuan B, Faucon G, et al. Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia. Cardiovasc Drugs Ther. 1996;10(4):447-54doi: 10.1007/BF00051109.
Timour, Q., Bui-Xuan, B., Faucon, G., & Aupetit, J. F. (1996). Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia. Cardiovascular drugs and therapy, 10(4), 447-54. https://doi.org/10.1007/BF00051109
Timour, Q, et al. "Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia." Cardiovascular drugs and therapy vol. 10,4 (1996): 447-54. doi: https://doi.org/10.1007/BF00051109
Timour Q, Bui-Xuan B, Faucon G, Aupetit JF. Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia. Cardiovasc Drugs Ther. 1996 Sep;10(4):447-54. doi: 10.1007/BF00051109. PMID: 8924058.
Copy Download .nbib Format: NLM
Share it on

Cardiovasc Drugs Ther. 1996 Sep;10(4):447-54. doi: 10.1007/BF00051109.

Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia.

Cardiovascular drugs and therapy

Q Timour, B Bui-Xuan, G Faucon, J F Aupetit

Affiliations

  1. Department of Medical Pharmacology, Cl. Bernard University, Lyon, France.

PMID: 8924058 DOI: 10.1007/BF00051109

Abstract

Calcium antagonists have been reported to counteract the increase by ischemia of vulnerability to ventricular fibrillation. This ability might be especially of interest in the prevention of sudden death subsequent to a major, but transitory, inadequacy between myocardial oxygen requirements and available coronary blood flow produced by exercise, emotion, etc., because death is then not related to irreversible damage of myocardial fibers. This study has been undertaken to examine the protective effect of a calcium antagonist on an animal model of this type of ischemia. This model used complete, but transient occlusion of the left anterior descending coronary artery near its origin during pacing at a constant high rate (180 beats/min) in anesthetized, open-chest pigs, most often resulting in fibrillation within 1-2 minutes after a progressive fall of the electrical fibrillation threshold. Amlodipine was the preferred calcium antagonist for this study because it is only moderately negatively inotropic. The results of the preventive administration of amlodipine was assessed by the time to onset of fibrillation. Amlodipine 0.30 mg/kg prolonged this time by 50-100% (p < 0.05) without appreciable impairment of blood pressure or myocardial contractility. Concurrently, amlodipine delayed the shortening of the monophasic action potential duration, the lengthening of conduction time, and the alterations of ST segments and T waves linked to ischemic depolarization. Consequently, when given experimentally before the occurrence of major, but transitory ischemia, amlodipine protected against fibrillation. Similarly, in clinical settings it ought to delay sudden death that may occur as a result of a major but transitory inadequacy between myocardial oxygen requirements and available coronary blood flow.

References

  1. Circulation. 1986 Nov;74(5):1124-36 - PubMed
  2. Circ Res. 1984 Jan;54(1):10-20 - PubMed
  3. J Pharmacol Exp Ther. 1968 Dec;164(2):326-32 - PubMed
  4. Circulation. 1977 Feb;55(2):311-7 - PubMed
  5. Eur J Pharmacol. 1986 Aug 15;127(3):261-5 - PubMed
  6. N Engl J Med. 1988 Aug 18;319(7):385-92 - PubMed
  7. Am Heart J. 1978 Jul;96(1):81-6 - PubMed
  8. JAMA. 1988 Oct 14;260(14):2088-93 - PubMed
  9. Physiol Rev. 1989 Oct;69(4):1049-169 - PubMed
  10. Eur Heart J. 1984 Jan;5(1):7-20 - PubMed
  11. J Physiol. 1955 Jan 28;127(1):213-24 - PubMed
  12. Drugs. 1991;42 Suppl 2:38-42 - PubMed
  13. BMJ. 1989 Nov 11;299(6709):1187-92 - PubMed
  14. Am Heart J. 1982 Apr;103(4 Pt 2):698-706 - PubMed
  15. Am Heart J. 1983 Nov;106(5 Pt 1):1023-8 - PubMed
  16. Cardiovasc Drugs Ther. 1989 Aug;3(4):545-55 - PubMed
  17. J Clin Pharmacol. 1988 Nov;28(11):990-4 - PubMed
  18. Am J Physiol. 1978 Feb;234(2):H101-16 - PubMed
  19. Am J Cardiol. 1982 Feb 18;49(3):606-12 - PubMed
  20. Annu Rev Physiol. 1984;46:473-84 - PubMed
  21. Cardiovasc Res. 1992 May;26(5):487-95 - PubMed
  22. Circulation. 1984 Oct;70(4):734-41 - PubMed
  23. Am J Cardiol. 1990 Oct 1;66(10):779-85 - PubMed
  24. Cardiovasc Res. 1980 May;14(5):295-302 - PubMed
  25. Am J Cardiol. 1987 Jan 30;59(3):84B-94B - PubMed
  26. Am J Cardiol. 1977 Apr;39(4):544-9 - PubMed
  27. Am J Cardiol. 1987 Jan 30;59(3):75B-83B - PubMed
  28. Eur Heart J. 1984 Jul;5(7):516-28 - PubMed
  29. Fundam Clin Pharmacol. 1991;5(7):641-4 - PubMed
  30. Circulation. 1987 Nov;76(5):1146-54 - PubMed
  31. Arch Int Pharmacodyn Ther. 1994 Jan-Feb;327(1):25-39 - PubMed
  32. Drugs. 1991;42 Suppl 1:7-13 - PubMed
  33. Drugs. 1991;42 Suppl 2:43-53 - PubMed
  34. Naunyn Schmiedebergs Arch Pharmacol. 1993 Nov;348(5):509-14 - PubMed
  35. Circ Res. 1991 Jan;68(1):61-8 - PubMed
  36. J Mol Cell Cardiol. 1982 Jan;14(1):21-32 - PubMed
  37. Cardiovasc Drugs Ther. 1991 Dec;5(6):1035-41 - PubMed
  38. Am Heart J. 1977 Dec;94(6):755-63 - PubMed
  39. J Cardiovasc Pharmacol. 1988;12 Suppl 7:S55-9 - PubMed

Substances

MeSH terms

Publication Types